


General description

Testicular germ cell tumour  Ovarian germ cell tumour  Osteosarcoma  Rhabdomyosarcoma  Ewing sarcoma.

INN	Mesna
Medicine type	Chemical agent
EML status history	<p>First added in 2009 (TRS 958) for Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Added in 2015 (TRS 994) for Osteosarcoma of bone and articular cartilage of other specified sites</p> <p>Added in 2015 (TRS 994) for Rhabdomyosarcoma primary site</p> <p>Added in 2015 (TRS 994) for Other specified malignant neoplasms of the ovary</p> <p>Added in 2015 (TRS 994) for Germ cell tumour of testis</p> <p>Added in 2015 (TRS 994) for Ewing sarcoma of bone and articular cartilage of unspecified sites</p> <p>Removed in 2015 (TRS 994) for Unspecified malignant neoplasms of ill-defined or unspecified sites</p>
Therapeutic equivalent for	
Wikipedia	Mesna 
DrugBank	Mesna (Coenzyme M) 

Recommendations

Section Supportive medicines

Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
 Oral > Solid: 400 mg; 600 mg

Indications

- Osteosarcoma of bone and articular cartilage of other specified sites
- Rhabdomyosarcoma primary site
- Other specified malignant neoplasms of the ovary
- Germ cell tumour of testis
- Ewing sarcoma of bone and articular cartilage of unspecified sites
- Unspecified malignant neoplasms of ill-defined or unspecified sites

